National Comprehensive Cancer Network

Interactive CME


Educational Events & Programs


DATES > Friday, October 6 – Saturday, October 7, 2017
            LEARN MORE>

LOCATION > Hilton San Francisco Union Square • San Francisco, California

Additional Programs:
Save the Date!
NCCN Global Academy > Friday, October 6, 2017          LEARN MORE>

New Program for Nurses!
NCCN Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™ > Friday, October 6, 2017            LEARN MORE>


Early bird registration discount ends on Friday, August 25!

Overview

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

Co-Chairs:


Ranjana H. Advani, MD
Stanford Cancer Institute



Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

 

Agenda*

Friday, October 6, 2017

4:30 PM – 8:35 PM

Registration Desk Opens

4:30 PM– 6:00 PM

Refreshments and Exhibits

6:00 PM  -  6:15 PM

Opening Remarks

Moderators:

  • Ranjana H. Advani, MD, 
  • Andrew D. Zelenetz, MD, PhD 
6:15 PM  -  6:40 PM

WHO Classification of Lymphoma: A Clinician’s Perspective

6:45 PM  -  7:10 PM

Updates on the Treatment of Follicular Lymphoma

7:15 PM  -  7:40 PM

New Options for the Management of Hodgkin Lymphoma

7:45 PM  -  8:35 PM

Patient Case Studies and Panel Discussions: Lymphoma

 

Saturday, October 7, 2017

6:30 AM  -  5:00 PM

Registration Desk Opens

7:00 AM  -  8:00 AM

Breakfast and Exhibits

8:00 AM  -  8:05 AM

Opening Remarks

Moderators:

  • Ranjana H. Advani, MD, 
  • Andrew D. Zelenetz, MD, PhD
8:05 AM  -  8:45 AM

Managing Lymphoma Survivors

8:50 AM  -  9:40 AM

Patient Case Studies and Panel Discussions: Plasma Cell Neoplasms

9:45 AM  -  10:10 AM

Management of Newly Diagnosed Multiple Myeloma in Those Eligible for Transplant

10:10 AM  -  10:40 AM

Break and Exhibits

10:40 AM  -  11:05 AM

Treatment of Relapsed/Refractory Multiple Myeloma

11:10 AM  -  11:35 AM

Management of Common Complications Related to Multiple Myeloma and its Treatment

11:40 AM  -  12:05 PM

Palliative and End of Life Care in Hematological Malignancies

12:05 PM  -  1:05 PM

Lunch and Exhibits

1:05 PM  -  1:55 PM

Patient Case Studies and Panel Discussions: Leukemia

2:00 PM  -  2:25 PM

Myeloproliferative Neoplasms: Management of Polycythemia Vera and Essential Thrombocythemia

2:30 PM  -  2:55 PM

How to Sequence Therapy in Chronic Lymphocytic Leukemia

3:00 PM  -  3:25 PM

New Therapeutic Agents and Considerations in the Management of Acute Lymphocytic Leukemia

3:25 PM  -  3:50 PM

Break and Exhibits

3:50 PM  -  4:15 PM

Targeted Therapy for Acute Myeloid Leukemia

4:20 PM  -  5:00 PM

Controversies in Acute Myeloid Leukemia: Is Monitoring Minimal Residual Disease Clinically Relevant?

5:00 PM 

Closing Remarks

Moderators:

  • Ranjana H. Advani, MD, 
  • Andrew D. Zelenetz, MD, PhD 

 

*This agenda is subject to change. Faculty will be updated as confirmed.


Supporter Opportunities

Organizations who are interested in supporting NCCN CE programs are encouraged to contact Lisa Perfidio.

Sponsorship and exhibit opportunities are available. For more information, contact Jennifer Tredwell.


EXHIBITOR INFORMATION

NCCN 12th Annual Congress: Hematologic Malignancies™ - Sponsor and Exhibitor Prospectus

NCCN 12th Annual Congress: Hematologic Malignancies™ - Advertising Rate Card


Recorded Presentations
Earn up to 8.75 credits with recorded presentations from the NCCN 11th Annual Congress: Hematologic Malignancies™ that took place September 30 - October 1, 2016 in New York, NY.

Recorded Lunch Symposium – The Future of Targeted Therapies for Acute Myeloid Leukemia
Earn .75 credit! This activity is designed to address the unprecedented recent and ongoing advances in AML research and anticipated changes in the AML therapeutic landscape resulting from the development of many innovative therapies, several of which are in late stages of clinical trials.

For a complete list of available recordings from the NCCN 11th Annual Congress: Hematologic Malignancies, please visit education.nccn.org/hem2016.


Please check back often for the most up-to-date information. Please contact 866.788.NCCN (6226) or send an e-mail if you have additional questions.